This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Asensus Surgical Crescita futura

Future criteri di controllo 2/6

Si prevede che Asensus Surgical aumenterà gli utili e i ricavi rispettivamente del 56.1% e 52.1% all'anno, mentre si prevede che l'EPS crescerà del 58% all'anno.

Informazioni chiave

56.1%

Tasso di crescita degli utili

58.0%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	17.4%
Tasso di crescita dei ricavi	52.1%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	16 May 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

NYSEAM:ASXC - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	51	-26	N/A	N/A	1
12/31/2025	22	-61	N/A	N/A	2
12/31/2024	12	-66	N/A	N/A	2
6/30/2024	10	-84	-57	-57	N/A
3/31/2024	9	-79	-61	-60	N/A
12/31/2023	9	-78	-64	-64	N/A
9/30/2023	6	-79	-65	-64	N/A
6/30/2023	7	-80	-65	-64	N/A
3/31/2023	7	-79	-61	-60	N/A
12/31/2022	7	-76	-60	-59	N/A
9/30/2022	7	-74	-59	-58	N/A
6/30/2022	7	-71	-54	-52	N/A
3/31/2022	7	-64	-48	-46	N/A
12/31/2021	8	-62	-42	-41	N/A
9/30/2021	7	-60	-41	-40	N/A
6/30/2021	5	-59	-41	-40	N/A
3/31/2021	5	-60	-45	-44	N/A
12/31/2020	3	-60	-47	-47	N/A
9/30/2020	3	-60	-48	-48	N/A
6/30/2020	4	-143	-59	-59	N/A
3/31/2020	7	-149	-62	-62	N/A
12/31/2019	9	-154	-74	-73	N/A
9/30/2019	15	-147	-73	-72	N/A
6/30/2019	19	-69	-69	-69	N/A
3/31/2019	22	-83	-61	-60	N/A
12/31/2018	24	-62	-49	-48	N/A
9/30/2018	20	-131	-46	-45	N/A
6/30/2018	15	-150	-42	-41	N/A
3/31/2018	10	-130	N/A	-46	N/A
12/31/2017	7	-145	N/A	-47	N/A
9/30/2017	4	-83	N/A	-53	N/A
6/30/2017	5	-57	N/A	-50	N/A
3/31/2017	3	-122	N/A	-51	N/A
12/31/2016	2	-120	N/A	-52	N/A
9/30/2016	1	-120	N/A	-51	N/A
6/30/2016	N/A	-121	N/A	-50	N/A
3/31/2016	N/A	-50	N/A	-45	N/A
12/31/2015	N/A	-47	N/A	-39	N/A
9/30/2015	0	-41	N/A	-34	N/A
6/30/2015	0	-39	N/A	-36	N/A
3/31/2015	0	-40	N/A	-35	N/A
12/31/2014	0	-38	N/A	-33	N/A
9/30/2014	0	-38	N/A	-31	N/A
6/30/2014	1	-37	N/A	-27	N/A
3/31/2014	1	-31	N/A	-24	N/A
12/31/2013	1	-28	N/A	-21	N/A
9/30/2013	2	-24	N/A	-17	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ASXC rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ASXC rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ASXC rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ASXC ( 52.1% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ASXC ( 52.1% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ASXC è previsto essere elevato tra 3 anni

This company has been acquired

Asensus Surgical Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates fall by 20%

Consensus revenue estimates increase by 10%

Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023

Consensus EPS estimates fall by 23%

Consensus revenue estimates fall by 34%

Price target decreased by 21% to US$1.75

Recent updates

Asensus Surgical, Inc.(NYSEAM:ASXC) dropped from S&P TMI Index

KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC).

New major risk - Negative shareholders equity

Asensus Surgical, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology

New major risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 20%

Asensus Surgical, Inc. to Report Q1, 2024 Results on May 14, 2024

KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million.

Full year 2023 earnings: EPS exceeds analyst expectations

Asensus Surgical, Inc. to Report Q4, 2023 Results on Mar 21, 2024

President exercised options and sold US$131k worth of stock

Consensus revenue estimates increase by 10%

Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023

Asensus Surgical, Inc. Develops the LUNA Surgical System

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Asensus Surgical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Asensus Surgical, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Share price stability

Consensus EPS estimates fall by 23%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Price target decreased by 21% to US$1.75

Full year 2022 earnings: EPS exceeds analyst expectations

President exercised options and sold US$406k worth of stock

Asensus Surgical, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Insufficient new directors

Consensus revenue estimates fall by 17%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$2.25

Asensus Surgical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Asensus Surgical, Inc. Announces Impairment Charges for Three Months Ended June 30, 2022

Asensus Surgical, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Asensus Surgical, Inc. to Showcase the Senhance Surgical System and Performance-Guided Surgery in Upcoming Society of Robotic and Digital Surgery Conference

Asensus Surgical, Inc., Annual General Meeting, Jun 14, 2022

Asensus Surgical, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Asensus Surgical, Inc. Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific Center

Asensus Surgical Receives FDA 510(k) Clearance for Expansion of Machine Vision Capabilities

Asensus Surgical, Inc. to Report Q4, 2020 Results on Mar 11, 2021

Asensus Surgical Announces FDA Clearance in General Surgery

TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $69.249999 million.

TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $31.25 million.

TransEnterix, Inc. Announces Southern Surgical Hospital to Initiate a Senhance Digital Laparoscopic Program

TransEnterix Announces Approval of Senhance Surgical System in Russian Federation

Transenterix, Inc. Does Not Provide Forward-Looking Guidance

TransEnterix, Inc. to Report Q3, 2020 Results on Nov 05, 2020

TransEnterix, Inc. Announces First Pediatric Surgical Cases with Senhance® Surgical System

TransEnterix Announces Toshima Hospital in Japan to Initiate A Senhance® Digital Laparoscopy Program

Transenterix, Inc. Not Provide Revenue Guidance

TransEnterix, Inc. Contemplates Bankruptcy

TransEnterix, Inc. to Report Q2, 2020 Results on Aug 05, 2020

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Growth Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2000 Dynamic Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Value Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2500 Growth Index

TransEnterix, Inc.(AMEX:TRXC) dropped from S&P Global BMI Index

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita